Power Wheelchair Group 3 denied as experimental or investigational by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for power wheelchair group3 are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Denies Power Wheelchair (Group 3) as Experimental

A Group 3 power wheelchair classified as experimental or investigational by UHC typically means the specific device model, a particular seating system component, or an integrated technology feature has not yet been recognized in UHC's coverage policy as proven and effective. Insurers distinguish between the broader category (power mobility devices — which are well-established and CMS-covered) and specific sub-features such as advanced power positioning, alternative drive controls, or newer connectivity hardware. UHC may cite the absence of sufficient peer-reviewed evidence for a specific feature while the core power wheelchair itself is uncontested.

This denial is highly appealable because Group 3 complex rehabilitation technology (CRT) as a category has extensive clinical backing and regulatory recognition. The denial often rests on a narrow reading of a single feature rather than the device as a whole.

## Your Federal Appeal Rights

Under ACA §2719, you have the right to an independent external review by a certified independent review organization (IRO) after exhausting UHC's internal appeals process. Under ERISA §503 (self-funded plans), you are entitled to full-and-fair review with access to the evidence and rationale UHC used. The external-review window generally runs approximately four months from the denial notice — file promptly. Request expedited review if waiting for a device is causing functional harm or safety risk at home.

## What to Gather Before You Write Your Appeal

• Device prescription and justification: a detailed letter of medical necessity from your prescribing physician and, where applicable, a certified ATP, explaining why each component of the prescribed device — including any advanced features — is individually necessary for your diagnosis and functional level.
• CMS coding documentation: confirm that the device is assigned a recognized HCPCS code by the Centers for Medicare and Medicaid Services; commercial insurers rarely sustain an experimental denial on devices CMS has assigned billing codes to.
• UHC's coverage policy: request UHC's current published Medical Policy and identify exactly which feature or component was labeled experimental. Your appeal should address that specific language.
• Clinical support literature: ask your prescribing physician or ATP to reference relevant guidelines from the Rehabilitation Engineering and Assistive Technology Society of North America (RESNA) or applicable clinical organizations — without citing specific statistics.

## Criteria-Mapping Structure

For each feature or component UHC labeled experimental, document:

| Feature UHC Challenged | Clinical Justification | Regulatory / Coding Status | |---|---|---| | [Specific component] | [Physician/ATP rationale from chart] | [HCPCS code; CMS coverage status] |

A point-by-point response to UHC's experimental designation — anchored in the chart and in the device's regulatory history — is the most effective appeal format.